A Phase Iii Randomized Study Of Neoadjuvant Chemotherapy (Nac) Alone Or In Combination With Nivolumab (Nivo) +/- Linrodostat Mesylate, Followed By Adjuvant Postsurgical Nivo +/- Linrodostat, In Cisplatin-Eligible Muscle Invasive Bladder Cancer (Mibc).

Guru Sonpavde,Andrea Necchi,Shilpa Gupta,Gary D. Steinberg,Juergen Gschwend,Michiel Simon Van Der Heijden, Audrey Richiero,Alexandre Lambert,Bradley Raybold, Srikanth Gajavelli,Dimitrios Zardavas,Matt D. Galsky

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited 2|Views9

No score

Abstract

TPS5091Background: Immuno-oncology (IO) therapies have revolutionized the treatment (tx) of pts with advanced bladder cancer (advBC). For pts with cisplatin-eligible, muscle invasive BC (MIBC), the...

Translated text

Key words

invasive bladder cancer,neoadjuvant chemotherapy,cisplatin-eligible

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined